PARPi accomplishes antitumor efficacy by activating the cGAS-STING pathway, recruiting CD8+ T cells, and inducing type 1 interferon (IFN) signaling, thereby resetting or initiating the tumor microenvironment (159). Here, IFNA1 is linked to neoplasm.